Enovis (ENOV)
NYSE:ENOV
Want to see ENOV full AI Analyst Report?
ENOV Stock Chart & Stats
$26.32
$0.83(1.85%)
At close: 4:00 PM EST
$26.32
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$21.00 - $37.85
Previous CloseN/A
Volume391.51K
Average Volume (3M)795.09K
Market Cap
$1.36B
Enterprise Value$2.65B
Total Cash (Recent Filing)$36.39M
Total Debt (Recent Filing)$1.38B
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 07, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding57,300,630
10 Day Avg. Volume726,630
30 Day Avg. Volume795,092
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap1.95
Enterprise Value/Revenue1.18
Enterprise Value/Gross Profit1.97
Enterprise Value/Ebitda-3.22
Forecast
1Y Price Target
$43.60Price Target Upside65.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)3.55
Revenue Forecast (FY)$2.34B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationMeaningful free cash flow generation combined with maintained adjusted EBITDA margins provides financial flexibility to fund innovation, reduce leverage, and support shareholder value.
Margin ImprovementExpanded adjusted gross margins from a favorable product mix and manufacturing initiatives indicate improving core profitability that can support stronger reported earnings and valuation upside.
Product CommercializationRelaunch of the Arvis augmented reality surgical guidance system alongside new shoulder, hip and knee product rollouts could drive market share by offering a lower-cost, flexible alternative to robotic platforms and appealing to ambulatory surgery centers.
Bears Say
Procedure Demand WeaknessUneven U.S. hip and knee procedure growth creates top-line uncertainty and sustains investor concern about the sustainability of revenue recovery.
Revenue Guidance CutLowered revenue guidance that came in below analyst expectations signals a weaker sales outlook and raises questions about the company's near-term execution against targets.
Seasonal Ordering SoftnessSeasonal ordering softness across multiple regions and product lines introduces short-term sales volatility and complicates forecasting and operational planning.
Enovis News
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $21.00 and its highest was $37.85 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.36B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is May 07, 2026 which is in 13 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Feb 26, 2026. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.11.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.81.
How many shares outstanding does Enovis have?
Enovis has 57,300,630 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.95 in its last earnings report, beating expectations of $0.84. Following the earnings report the stock price went up 13.889%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.60 (65.65% Upside)
$43.60 (65.65% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 144.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $145.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.64%
12-Months-Change
Fundamentals
Return on Equity
-54.42%
Trailing 12-Months
Asset Growth
-18.73%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial story: sustainable organic growth (6% full‑year), strong Recon performance (8% organic; 10% international), margin expansion at the gross level (+170 bps), a return to positive free cash flow and improved leverage/interest expense. Management also highlighted a robust innovation pipeline and actionable 2026 guidance that targets continued growth and improved cash conversion. Notable negatives include a sizeable $501M goodwill impairment, tariff impacts (~$15M), execution shortcomings in Q4 (4 fewer selling days / admitted missed execution), and ongoing integration and investment costs (including a $41M revenue headwind from the Dr. Comfort divestiture). On balance, the material positives around growth, margins, cash flow improvement, portfolio momentum and a clear 2026 outlook outweigh the lowlights, though shareholders should monitor the implications of the impairment, tariff exposure and near‑term operational cadence.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$43.60
▲(65.65% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---